Australia - English - Department of Health (Therapeutic Goods Administration)

boston scientific pty ltd - 62218 - coronary angioplasty balloon catheter, drug-eluting - the agent monorail ptca balloon catheter has a semi-compliant balloon coated with a formulation of paclitaxel (drug) and an excipient that is designed to inhibit restenosis by delivering drug to diseased arterial tissue. the outer lumen is used for inflation of the balloon, and the inner lumen permits the use of guidewires to facilitate advancement of the catheter. the balloon is designed to provide an inflatable segment of known diameter and length at recommended pressures. the agent balloon catheter is indicated for percutaneous transluminal coronary angioplasty (ptca) in the coronary arteries to treat in-stent restenosis (isr) and de novo / small vessel disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

bio-excel australia pty ltd - 35094 - catheter guide wire - gladius ptca guide wire is used to facilitate selection of the blood vessel and distal radiopaque section enables confirmation of the position of the guide wire distal end by fluoroscopy during pci procedure. asahi ptca guide wires are intended to facilitate the placement of balloon dilatation catheters during percutaneous transluminal coronary angioplasty (ptca).

Singapore - English - HSA (Health Sciences Authority)

alvimedica singapore pte ltd - general hospital - the invader™ ptca balloon dilatation catheter is intended to be used for dilating stenoses in the coronary artery or bypass graft so as to increase myocardial perfusion. • patients should be eligible for coronary bypass surgery. • it is indicated for patients with single-artery non-calcified atherosclerotic lesions that can be dilated using a ptca catheter. • this procedure can also be indicated in certain patients who have multi-artery disease, and in patients who have undergone aortacoronary bypass surgery but still have: > recurrent symptoms; > progressive coronary artery disease; > stenosis or obstruction in bypass grafts.

Egypt - English - EDA (Egyptian Drug Authority)

جامـــا ميـــد للتوريدات و الاستيراد -

Egypt - English - EDA (Egyptian Drug Authority)

جاما ميد للتوريدات -

Egypt - English - EDA (Egyptian Drug Authority)

جاما ميد للتوريدات -

Egypt - English - EDA (Egyptian Drug Authority)

جاما ميد للتوريدات -

Israel - English - Ministry of Health

medison pharma ltd - ataluren - granules for oral suspension - ataluren 1000 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

Israel - English - Ministry of Health

medison pharma ltd - ataluren - granules for oral suspension - ataluren 1000 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

Israel - English - Ministry of Health

medison pharma ltd - ataluren - granules for oral suspension - ataluren 1000 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.